This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).
The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.
The discovery of the S1-4-A09 antibody and its A80P derivative from a survivor of Ebola virus disease represents a significant advancement in the development of therapeutics against Ebola virus. These antibodies, isolated using innovative techniques, demonstrate potent antiviral activities in vitro and have shown improved stability and manufacturing feasibility compared to existing antibodies.
The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain's C-terminus within the ribosome's A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized.
The technology offers a novel and efficient method for inducing targeted DNA recombination using a tripartite fusion protein, LFn-NLS-Cre, in combination with anthrax toxin protective antigen (PA). This system enables precise genetic manipulation in cells carrying a gene flanked by loxP sites, allowing for specific recombination events.
The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions.
The technology pertains to a novel multivalent peptide tolerogen designed for the therapeutic treatment of Multiple Sclerosis (MS), a condition where the immune system erroneously attacks the central nervous system. This advanced therapeutic strategy involves a fusion-peptide composed of myelin oligodendrocyte glycoprotein (MOG), myelin-basic protein (MBP), and myelin proteolipid protein (PLP), along with myelin-associated glycoprotein (MAG).
The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.
The technology involves the adaptation of CHO-DG44 cells to ActiCHO P medium, improving their doubling time and suitability for generating stable cell lines for GMP purposes. These stable cell lines are designed for expressing the RSV F protein stabilized in the prefusion conformation, including the DS-Cav1 mutation, developed by the Vaccine Research Center.
The technology involves a laboratory-derived version of the 2009 pandemic H1N1 virus, produced under Good Manufacturing Practices (GMP) to ensure safety and reproducibility for human studies. It's designed for use in controlled research settings to advance our understanding of influenza pathogenesis and to assess the efficacy of vaccines and drugs.